cGAS goes viral: A conserved immune defense system from bacteria to humans.

Jenson JM, Chen ZJ. 

Mol Cell. 2024 

Ubiquitin-like conjugation by bacterial cGAS enhances anti-phage defence. 

Jenson, J.M., Li, T., Du, F., Ea, C.-K. & Chen, Z.J. 

Nature 2023

Bacteria sting viral invaders. 

Jenson J., Chen ZJ. 

Nature. 2020 

Tertiary structural motif sequence statistics enable facile prediction and design of peptides that bind anti-apoptotic Bfl-1 and Mcl-1. 

Frappier V.*, Jenson, J.M.*, Zhou J.,  Grigoryan G., Keating, A.E. 

*These authors contributed equally to this work.

Structure 2019

Peptide design by optimization on a data-parameterized protein interaction landscape. 

Jenson, J.M.*, Xue V.*,  Stretz, L., Mendal, T., Reich L.L., Keating, A.E 

*These authors contributed equally to this work.

PNAS 2018

Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells. 

Araghi, R.R., Bird G.H., Ryan J.A., Jenson J.M., Godes M., Pritz J.R., Grant R.A., Letai A., Walensky L.D. and Keating A.E. 

PNAS 2018

Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. 

Jenson, J.M., Ryan, J.A., Grant R.A, Letai, A., Keating, A.E. 

eLife 2017

Patents

“Selective BFL-1 Peptides,”

Amy Keating, Justin Michael JENSON

U.S. Patent 11,198,715 B2, filed 2017-07-21, and issued 2021-12-14.

“Selective BFL-1 Inhibiting Peptides,”

Amy Keating, Justin Michael JENSON 

Filed Fall 2018.